Physiologically-based pharmacokinetic modeling for mirabegron: a multi-elimination pathway mediated by cytochrome P450 3A4, uridine 5'-diphosphate-glucuronosyltransferase 2B7, and butyrylcholinesterase

References

• Abrams P, Cardozo L, Fall M, et al. (2002). The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21:167–78.
   PubMed Web of Science ®Google Scholar
• Cook DR, Stiller RL, Weakly JN, et al. (1989). In vitro metabolism of mivacurium chloride (BW B1090U) and succinylcholine. Anesth Analg 68:452–6.
   PubMed Web of Science ®Google Scholar
• Darwich AS, Pade D, Ammori BJ, et al. (2012). A mechanistic pharmacokinetic model to assess modified oral drug bioavailability post bariatric surgery in morbidly obese patients: interplay between CYP3A gut wall metabolism, permeability and dissolution. J Pharm Pharmacol 64:1008–24.
   PubMed Web of Science ®Google Scholar
• Groen-Wijnberg M, Van Dijk J, Krauwinkel W, et al. (2017). Pharmacokinetic interactions between mirabegron and metformin, warfarin, digoxin or combined oral contraceptives. Eur J Drug Metab Pharmacokinet 42:417–29.
   PubMed Web of Science ®Google Scholar
• Herschorn S, Barkin J, Castro-Diaz D, et al. (2013). A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the beta(3) adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology 82:313–20.
   PubMed Web of Science ®Google Scholar
• Jamei M, Marciniak S, Edwards D, et al. (2013). The simcyp population based simulator: architecture, implementation, and quality assurance. In Silico Pharmacol 1:9.
   PubMedGoogle Scholar
• Jamei M, Marciniak S, Feng K, et al. (2009). The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol 5:211–23.
   PubMed Web of Science ®Google Scholar
• Jann MW, Shirley KL, Small GW. (2002). Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 41:719–39.
   PubMed Web of Science ®Google Scholar
• Khullar V, Amarenco G, Angulo JC, et al. (2013). Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol 63:283–95.
   PubMed Web of Science ®Google Scholar
• Konishi K, Tenmizu D, Takusagawa S. (2018). Identification of uridine 5'-Diphosphate-Glucuronosyltransferases responsible for the glucuronidation of mirabegron, a potent and selective beta3-adrenoceptor agonist, in human liver microsomes. Eur J Drug Metab Pharmacokinet 43:301–9.
   PubMed Web of Science ®Google Scholar
• Krauwinkel W, Dickinson J, Schaddelee M, et al. (2014). The effect of mirabegron, a potent and selective beta3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol. Eur J Drug Metab Pharmacokinet 39:43–52.
   PubMed Web of Science ®Google Scholar
• Krauwinkel W, Van Dijk J, Schaddelee M, et al. (2012). Pharmacokinetic properties of mirabegron, a beta3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women. Clin Ther 34:2144–60.
   PubMed Web of Science ®Google Scholar
• Lee J, Moy S, Meijer J, et al. (2013). Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist. Clin Drug Investig 33:429–40.
   PubMed Web of Science ®Google Scholar
• Milsom I, Abrams P, Cardozo L, et al. (2001). How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87:760–6.
   PubMed Web of Science ®Google Scholar
• Nitti VW, Khullar V, Van Kerrebroeck P, et al. (2013). Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Int J Clin Pract 67:619–32.
   PubMed Web of Science ®Google Scholar
• Østergaard D, Viby-Mogensen J, Pedersen NA, et al. (2002). Pharmacokinetics and pharmacodynamics of mivacurium in young adult and elderly patients. Acta Anaesthesiol Scand 46:684–91.
   PubMed Web of Science ®Google Scholar
• Rowland M, Peck C, Tucker G. (2011). Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol 51:45–73.
   PubMed Web of Science ®Google Scholar
• Rowland Yeo K, Jamei M, Yang J, et al. (2010). Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut – the effect of diltiazem on the time-course of exposure to triazolam. Eur J Pharm Sci 39:298–309.
   PubMed Web of Science ®Google Scholar
• Shebley M, Sandhu P, Emami Riedmaier A, et al. (2018). Physiologically based pharmacokinetic model qualification and reporting procedures for regulatory submissions: a consortium perspective. Clin Pharmacol Ther 104:88–110.
   PubMed Web of Science ®Google Scholar
• Stewart WF, Van Rooyen JB, Cundiff GW, et al. (2003). Prevalence and burden of overactive bladder in the United States. World J Urol 20:327–36.
   PubMed Web of Science ®Google Scholar
• Takasu T, Ukai M, Sato S, et al. (2007). Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther 321:642–7.
   PubMed Web of Science ®Google Scholar
• Takusagawa S, Miyashita A, Iwatsubo T, Usui T. (2012a). In vitro inhibition and induction of human cytochrome P450 enzymes by mirabegron, a potent and selective beta3-adrenoceptor agonist. Xenobiotica 42:1187–96.
   PubMed Web of Science ®Google Scholar
• Takusagawa S, Van Lier JJ, Suzuki K, et al. (2012b). Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective beta(3)-adrenoceptor agonist, after oral administration to healthy male volunteers. Drug Metab Dispos 40:815–24.
   PubMed Web of Science ®Google Scholar
• Takusagawa S, Yajima K, Miyashita A, et al. (2012c). Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective beta3-adrenoceptor agonist. Xenobiotica 42:957–67.
   PubMed Web of Science ®Google Scholar
• Takusagawa S, Ushigome F, Nemoto H, et al. (2013). Intestinal absorption mechanism of mirabegron, a potent and selective β3-adrenoceptor agonist: involvement of human efflux and/or influx transport systems. Mol Pharm 10:1783–94.
   PubMed Web of Science ®Google Scholar
• The International Transporter, Giacomini C, Huang KM, Tweedie SM, et al. (2010). Membrane transporters in drug development. Nat Rev Drug Discov 9:215–36.
   PubMed Web of Science ®Google Scholar
• Wein AJ, Rovner ES. (2002). Definition and epidemiology of overactive bladder. Urology 60:7–12. Discussion 12.
   PubMed Web of Science ®Google Scholar
• Yamaguchi O, Chapple CR. (2007). Beta3-adrenoceptors in urinary bladder. Neurourol Urodyn 26:752.
   PubMed Web of Science ®Google Scholar
• Yamaguchi O, Marui E, Kakizaki H, et al. (2014). Phase III, randomised, double-blind, placebo-controlled study of the beta3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder. BJU Int 113:951–60.
   PubMed Web of Science ®Google Scholar